AFM
CDLX icon

Anson Funds Management’s Cardlytics CDLX Stock Holding History

Anson Funds Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$821K – 164
2024
Q2 		$821K Buy
+10,000
New +$1.08M 0.1% 115

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Anson Funds Management's CDLX Position: Q3 2024 in Review

Anson Funds Management sold out of Cardlytics (CDLX) in Q3 2024, closing a stake of 10,000 shares — an estimated $821K sold.

Anson Funds Management first reported a position in CDLX in Q2 2024 and held it in 1 quarter. The position peaked at $821K in Q2 2024. 111 funds tracked by Wall St. Rank hold CDLX as of Q3 2024.

  • Anson Funds Management reported no remaining Cardlytics position as of Q3 2024 after selling out during the quarter.
  • Anson Funds Management sold 10,000 Cardlytics shares in Q3 2024, an estimated $821K.
  • Anson Funds Management first reported a position in Cardlytics in Q2 2024 and held it in 1 quarter.
  • Anson Funds Management's Cardlytics position peaked at $821K in Q2 2024.
  • 111 funds tracked by Wall St. Rank held Cardlytics as of Q3 2024.

Based on Anson Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.